Fresenius Kabi sells cancer compounding business to NewCo Pharma

Published: 17-Feb-2015
Finance

Will focus on compounding for parenteral nutrition products in Germany going forward


Healthcare company Fresenius Kabi has sold its German subsidiary CFL to NewCo Pharma, a compounding company based in Mannheim, for an undisclosed sum.

Both companies specialise in IV oncology drug compounding.

CFL has compounding centres in Aschaffenberg and Munich as well as compounding pharmacies in Bonn (Compounding Rheinische), Mannheim (Fortune Manufacturing), Osnabruck (Onco Service) and Stuttgart (cas central compounding Baden-Wuerttemberg).

In 2014, CFL had sales of €77m.

Fresenius Kabi says it will remain active in compounding. In Germany, it will focus on parenteral nutrition products, an area that the company says 'offers attractive growth opportunities'.

  • Companies:
  • Fresenius-Kabi
See more

You may also like

Finance

Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site in Halden, Norway

Read more
Prange Group and its affiliate Adragos Pharma have announced  the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile  pharmaceutical production site in Halden, Norway

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Finance

Prange Group and Adragos Pharma to acquire Fresenius Kabi’s manufacturing site in Halden, Norway

Prange Group and its affiliate Adragos Pharma have announced  the signing of definitive agreements with Fresenius Kabi for the acquisition of the leading sterile  pharmaceutical production site in Halden, Norway
Ingredients

Vifor Pharma enters Chinese joint venture with Fresenius Kabi

Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Design & Build

Fresenius Kabi to invest $250 million to expand Melrose Park site in Illinois, US

Building work will start next year at generic injectables plant and will be completed in 2026
Distribution

BD divests Rx business and adds IV solutions

BD and Fresenius Kabi have also signed a 10-year supply and distribution agreement
Finance

Fresenius Kabi expands IV drug business in Latin America

Deal builds on long-term presence in Brazil and creates a strong base for further expansion
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Subscribe now